Related Experiment Video

Updated: Apr 3, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

11.0K

Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms

Jonine D Figueroa1, Stella Koutros1, Joanne S Colt1

  • 1Division of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).

Journal of the National Cancer Institute
|September 17, 2015
PubMed

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
125
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
65
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
118
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
97